IP Library Patent Application 11364381
Patent Application
App. No. 11/364,381

Epimers and isomers of tetrazole containing rapamycin analogs, methods of making and using the same

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/364,381
Abstract

Epimers and isomers of tetrazole-containing rapamycin analogs and a pharmaceutically acceptable salt or prodrug thereof, are immunomodulatory agents and are useful in the treatment of restenosis and immune and autoimmune diseases. Also disclosed are cancer-, fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method of inhibiting cancer, fungal growth, restenosis, post-transplant tissue rejection, and immune and autoimmune disease in a mammal. One particular preferred application of such isomers and epimers of tetrazole containing rapamycin and 42-Epi rapamycin analogs is in medicated devices and local vascular delivery wherein the stability and lipid solubility and subsequently diffusion through tissue and cell membranes are essential to the success of rapamycin containing combination devices.

Claims (16)

1 . A compound having the structure:

or a pharmaceutically acceptable salt or prodrug thereof.

2 . A compound having the structure:

or a pharmaceutically acceptable salt or prodrug thereof.

3 . A compound having the structure:

or a pharmaceutically acceptable salt or prodrug thereof.

4 . A compound having the structure:

or a pharmaceutically acceptable salt or prodrug thereof.

5 . A compound having the structure:

or a pharmaceutically acceptable salt or prodrug thereof.

6 . A compound having the structure:

or a pharmaceutically acceptable salt or prodrug thereof.

7 . A method of inhibiting the neointimal growth of vasculature after catheter and balloon intervention in a mammal, which comprises administering to the mammal an antifungally effective amount of any of the compounds of any one of claims 1 - 6 .

8 . A method of using any of the compounds of any one of claims 1 - 6 in combination with an implantable medical device.

9 . A method of using any of the compounds of any one of claims 1 - 6 as an antioxidant for a native rapamycin molecule to achieve therapeutic effects and enhanced stability.

10 . A method of combining any of the compounds of any one of claims 1 - 6 , with a native rapamycin molecule to achieve therapeutic effects and enhanced stability.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2007
From: CORDIS CORPORATION
To: WYETH
Reel/Frame 020234/0460 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2006
From: ZHAO, JONATHON Z.
To: CORDIS CORPORATION
Reel/Frame 018034/0722 →